Tilray Hit Record Revenue-and the Market Still Hasn't Repriced It

Record revenue makes the muted stock reaction harder to explain

Tilray just finished fiscal 2026 with record revenue, yet the shares still trade more like a speculative cannabis name than a diversified consumer platform.

That disconnect matters because the operating trend was not a one-quarter anomaly. Tilray delivered record Q1 net revenue, then record Q2 net revenue of $218 million, followed by record Q3 net revenue, and ended the year with record fiscal 2026 revenue and adjusted EBITDA. The tape is simply lagging the underlying business momentum.

Bulls see a company proving it can sustain growth across multiple business lines. Bears see a market that still needs more proof after years of cannabis-sector disappointments. That skepticism is understandable, but it also helps explain why Tilray still trades with a noticeable fear discount.

Tilray's portfolio is broad enough to deserve a different label

Tilray now operates well beyond a single cannabis narrative

Tilray is no longer asking investors to underwrite cannabis alone. It operates across over 20 countries in cannabis, beverage, wellness, and pharma distribution, holds over 60% market share in North American branded hemp wellness products, and reported its best quarterly net revenue in Company history in international cannabis. That makes the company harder to pigeonhole than the old cannabis-stock label suggests.

International cannabis and beverage expansion are adding depth

Even within cannabis, the business looks more integrated and less dependent on one market. International cannabis revenue grew 73% year over year, cannabis flower sales volume rose 100%, and Tilray maintained its number-one cannabis revenue position in Canada. At the same time, the roughly £40 million BrewDog acquisition broadens its beverage footprint across Europe, the Middle East, Australia, Asia-Pacific, and the U.S.

What investors should watch next is whether that mix shift keeps gaining relevance: - Are beverage and wellness becoming a larger, more durable part of the story? - Is international cannabis scaling without obvious margin strain? - Is management framing Tilray increasingly as a diversified platform rather than a legal-cannabis turnaround?

If those signals keep showing up, the old single-segment discount becomes harder to justify.

Profitability and balance-sheet improvement are the real story

Q1 showed better earnings quality, not just higher sales

In the first quarter, Tilray delivered net income, adjusted EBITDA increased 9%, and net cash used in operations improved by $34 million year over year. Those are important qualifiers. The story is no longer just top-line growth; it is also improving conversion into profit and cash.

The balance sheet got cleaner, which changes how investors should view the risk

Tilray reduced net debt to $4 million in Q1 and moved into a net cash position by Q2. For a company that still carries cannabis-sector baggage, that matters as much as another revenue record. A firmer balance sheet should lower the fear premium that has long weighed on the stock.

Q2 and Q3 reinforced the pattern

Q2 brought record net revenue of $218 million and Reaffirms Full-Year Adjusted EBITDA Guidance. Q3 then added record net revenue, record gross profit, record international cannabis revenue, and about $3.5 million in net cash alongside $265 million in cash and marketable securities. The event page also highlighted record fiscal 2026 revenue and adjusted EBITDA.

What to watch now: - Can adjusted EBITDA land inside or above the guided range? - Will cash management keep net debt near zero? - Will investors start linking record sales to profits instead of assuming cannabis margins remain permanently unstable?

If those signals hold, the discount should narrow.

Fourth-quarter continuity is the next test

Tilray is heading into its Fourth Quarter 2026 Earnings Call after a year defined by record revenue and record adjusted EBITDA. The key question is whether management can show that the full-year result was sustainable rather than a peak.

Catalysts and watchpoints

• Guidance is the first real test. The clearest signal is whether management continues to support its Fiscal Year 2026 Adjusted EBITDA Outlook of $62 Million – $72 Million.
• Mix should keep broadening the story. If management keeps emphasizing a diversified platform across cannabis, beverage, hospitality, and wellness, investors have less reason to anchor on the old single-segment discount.
• Rescheduling should be framed as upside, not the core thesis. U.S. Federal Cannabis Rescheduling Expected to Unlock New Market Opportunity for Tilray Medical Expansion into the U.S. could help sentiment, but it works best as a potential accelerator on top of operating proof.

What would weaken the case

If the fourth quarter looks more like a peak than a base case, or management cannot defend the prior EBITDA framework, bears will have a stronger argument. In that scenario, Tilray likely remains trapped as a cyclical cannabis trade rather than earning a durability multiple.